ATC-Code* | Wirkstoff | Bemerkung |
---|
A07A | Intestinale Antiinfektiva | |
A09AA02 | Multienzyme (Lipase, Protease etc.) | |
A10A | Insuline und Analoga | |
A11CC05 | Colecalciferol (Vitamin D3) | parenterale Formen |
A11DA01 | Thiamin (Vitamin B1) | parenterale Formen |
A11DB | Vitamin B1 in Kombination mit Vitamin B6 und/oder Vitamin B12 | parenterale Formen |
A11GA01 | Ascorbinsäure (Vitamin C) | parenterale Formen |
A11HA02 | Pyridoxin (Vitamin B6) | parenterale Formen |
A11HA04 | Riboflavin (Vitamin B2) | parenterale Formen |
A12CC02 | Magnesiumsulfat | parenterale Formen |
A12CE02 | Natriumselenit | parenterale Formen |
B01AA04 | Phenprocoumon | |
B01AA07 | Acenocoumarol | |
B01AB01 | Heparin | > 100 IE/mL |
B01AB02 | Antithrombin III | |
B01AB04 | Dalteparin | |
B01AB05 | Enoxaparin | |
B01AB06 | Nadroparin | |
B01AB09 | Danaparoid | |
B01AD02 | Alteplase | Dosierung > 2 mg |
B01AD04 | Urokinase | |
B01AD11 | Tenecteplase | |
B01AE03 | Argatroban | |
B01AE07 | Dabigatran | |
B01AF01 | Rivaroxaban | |
B01AF02 | Apixaban | |
B01AF03 | Edoxaban | |
B01AX05 | Fondaparinux | |
B02AA02 | Tranexamsäure | parenterale Formen |
B02BD | Blutgerinnungsfaktoren | |
B05AA01 | Albumin | |
B05BA01 | Aminosäuren | parenterale Formen |
B05BA02 | Fettemulsionen | parenterale Formen |
B05BA03 | Kohlenhydrate | parenterale Formen mit Glukose Konzentration ≥ 20 % w/V, Volumen > 50 ml |
B05BA10 | Lösungen zur parenteralen Ernährung, Kombinationen | zentralvenös formulierte 3-Kammerbeutelsysteme |
B05BB01 | Elektrolytlösungen | |
B05DB | Hypertone Lösungen zur Peritonealdialyse | |
B05XA14 | Dinatrium-1-glycerinphosphat | parenterale Formen |
B05XA31 | Elektrolyte, Kombinationen, inkl. reine Spurenelemente | parenterale Formen |
B05XB02 | Alanyl-glutamin | parenterale Formen |
B05XC | Vitamine | parenterale Formen |
B05ZB | Hämofiltrate | |
C01CA02 | Isoprenalin | |
C01CA03 | Noradrenalin | |
C01CA07 | Dobutamin | |
C01CA24 | Adrenalin | |
C03CA01 | Furosemid | parenterale Formen |
C07AB02 | Metoprolol | parenterale Formen |
C07AG01 | Labetalol | |
D08AC52 | Chlorhexidin, Kombinationen | Volumen > 100 mL |
D08AG02 | Iod-Povidon | Volumen > 100 mL |
D08AJ57 | Octenidin, Kombinationen | |
D08AX05 | Isopropanol | |
D08AX53 | Propanol, Kombinationen | |
G02AD05 | Sulproston | |
H01AA02 | Tetracosactid | |
H01BA02 | Desmopressin | parenterale Formen |
H01BB02 | Oxytocin | parenterale Formen |
H01BB03 | Carbetocin | |
J01 | Antibiotika zur systemischen Anwendung | ohne J01Z |
J02 | Antimykotika zur systemischen Anwendung | |
J04A | Mittel zur Behandlung der Tuberkulose | |
J05AB06 | Ganciclovir | |
J05AB14 | Valganciclovir | |
J05AD01 | Foscarnet | |
J05AH02 | Oseltamivir | |
J06BA01 | Humane Immunglobuline | unspezifisch, extravaskulär |
J06BA02 | Humane Immunglobuline | unspezifisch, intravaskulär |
J06BB01 | Anti-D-Immunglobulin | |
J06BB02 | Tetanus-Immunglobulin | |
J06BB03 | Varizella/Zoster Immunglobulin | |
J06BB04 | Hepatitis B-Immunglobulin | |
J06BB05 | Tollwut-Immunglobulin | |
J07 | Impfstoffe | |
L01AA01 | Cyclophosphamid | |
L01AA03 | Melphalan | |
L01AA06 | Ifosfamid | |
L01AA09 | Bendamustin | |
L01AB01 | Busulfan | |
L01AC01 | Thiotepa | |
L01AD01 | Carmustin | |
L01AX03 | Temozolomid | |
L01AX04 | Dacarbazin | |
L01BA01 | Methotrexat | parenterale Formen |
L01BB02 | Mercaptopurin | |
L01BB03 | Tioguanin | |
L01BB04 | Cladribin | parenterale Formen |
L01BB05 | Fludarabin | |
L01BB07 | Nelarabin | |
L01BC01 | Cytarabin | |
L01BC02 | Fluorouracil | |
L01BC05 | Gemcitabin | |
L01BC06 | Capecitabin | |
L01BC07 | Azacitidin | |
L01CA02 | Vincristin | |
L01CA04 | Vinorelbin | |
L01CB01 | Etoposid | |
L01CD01 | Paclitaxel | |
L01CD02 | Docetaxel | |
L01CD04 | Cabazitaxel | |
L01CE02 | Irinotecan | Alter ATC-Code |
L01CX01 | Trabectedin | |
L01DB01 | Doxorubicin | |
L01DB03 | Epirubicin | |
L01DC01 | Bleomycin | |
L01EA01 | Imatinib | |
L01EB04 | Osimertinib | |
L01EC02 | Dabrafenib | |
L01EE01 | Trametinib | |
L01EH02 | Neratinib | |
L01EL01 | Ibrutinib | |
L01EX04 | Vandetanib | |
L01EX10 | Midostaurin | |
L01FA01 | Rituximab | |
L01FB01 | Inotuzumab ozogamicin | |
L01FC01 | Daratumumab | |
L01FD01 | Trastuzumab | |
L01FD02 | Pertuzumab | |
L01FD03 | Trastuzumab emtansin | |
L01FE01 | Cetuximab | |
L01FF02 | Pembrolizumab | |
L01FF03 | Durvalumab | |
L01FF05 | Atezolizumab | |
L01FG01 | Bevacizumab | |
L01FG02 | Ramucirumab | |
L01FX02 | Gemtuzumab ozogamicin | |
L01FX04 | Ipilimumab | |
L01FX05 | Brentuximab vedotin | |
L01FX07 | Blinatumomab | |
L01XA01 | Cisplatin | |
L01XA02 | Carboplatin | |
L01XA03 | Oxaliplatin | |
L01XF01 | Tretinoin | |
L01XG01 | Bortezomib | |
L01XG02 | Carfilzomib | |
L01XH03 | Panobinostat | |
L01XJ01 | Vismodegib | |
L01XX05 | Hydroxycarbamid | |
L01XX23 | Mitotan | |
L01XX24 | Pegaspargase | |
L01XX27 | Arsentrioxid | |
L01XX52 | Venetoclax | |
L02AE03 | Goserelin | |
L02BA01 | Tamoxifen | |
L02BA03 | Fulvestrant | |
L03AX03 | BCG Impfstoff | |
L04AA04 | Antithymocytäres Immunglobulin (Kaninchen) | |
L04AA13 | Leflunomid | |
L04AB06 | Golimumab | |
L04AC02 | Basiliximab | |
L04AX01 | Azathioprin | perorale Formen |
L04AX03 | Methotrexat | perorale Formen |
L04AX04 | Lenalidomid | |
M01AB05 | Diclofenac | parenterale Formen |
M01AB15 | Ketorolac | parenterale Formen |
M01AE17 | Dexketoprofen | parenterale Formen |
M03AB01 | Suxamethonium | |
M03AC04 | Atracurium | |
M03AC09 | Rocuronium | |
M03AC11 | Cisatracurium | |
M03CA01 | Dantrolen | |
N01AB07 | Desfluran | |
N01AF03 | Thiopental | |
N01AH | Opioidanästhetika | parenterale Formen |
N01AH06 | Remifentanil | |
N01AX03 | Ketamin | |
N01AX10 | Propofol | |
N01BB02 | Lidocain | parenterale Formen |
N01BB03 | Mepivacain | |
N01BB04 | Prilocain | |
N02AA01 | Morphin | |
N02AA03 | Hydromorphon | |
N02AA05 | Oxycodon | |
N02AA08 | Dihydrocodein | exkl. Antitussiva |
N02AA55 | Oxycodon und Naloxon | |
N02AB02 | Pethidin | |
N02AB03 | Fentanyl | |
N02AE01 | Buprenorphin | |
N02AF02 | Nalbuphin | |
N02AJ06 | Codein und Paracetamol Kombination | |
N02AJ13 | Tramadol und Paracetamol Kombination | |
N02AX01 | Tilidin | |
N02AX02 | Tramadol | |
N02AX06 | Tapentadol | |
N02BA01 | Acetylsalicylsäure, inkl. Lysinacetylsalicylat | parenterale Formen |
N02BB02 | Metamizol, Natriumsalz | parenterale Formen |
N02BE01 | Paracetamol | parenterale Formen |
N03AX18 | Lacosamid | |
N05BA01 | Diazepam | parenterale Formen und Tropfen |
N05BA06 | Lorazepam | parenterale Formen |
N07BC02 | Methadon | |
N07BC05 | Levomethadon | |
R03CC02 | Salbutamol | parenterale Formen |
R03CC05 | Hexoprenalin | |
S01AD03 | Aciclovir | Augensalbe |
S01JA01 | Fluorescein | Augentropfen |
V03AB14 | Protamin | |
V03AB35 | Sugammadex | |
V03AE02 | Sevelamer | |
V03AE03 | Lanthan III-carbonat | |
V03AE05 | Eisen(III)-oxidhydroxid Saccharose-Stärke-Komplex | |
V03AE07 | Calciumacetat | |
V03AF03 | Calciumfolinat (Folinsäure) | |
V08AA | Wasserlösliche nephrotrope hochosmolare Röntgenkontrastmittel | |
V08AB | Wasserlösliche nephrotrope niederosmolare Röntgenkontrastmittel | |
V08BA | Bariumhaltige Röntgenkontrastmittel | |
V08CA | Paramagnetische Kontrastmittel | |
V08DA | Ultraschallkontrastmittel | |
- *
- Der ATC-Code (Code des Wirkstoffs im «Anatomical Therapeutic Chemical Classification System») kann in der offiziellen englischen Fassung auf der Website des «Collaborating Centre for Drug Statistics Methodology» der Weltgesundheitsorga-nisation (WHO) unter folgender Adresse abgerufen werden: www.whocc.no > ATC/DDD Index. Die Zuteilung der Produkte folgt der ATC-Einteilung des Schweizerischen Heilmittelinstituts.
|